17 pharmaceutical executives leave! 5 pharmaceutical companies were put in! Medical workplace overhaul?

Guide: Is the industry's big change coming? A new round of major adjustment in the pharmaceutical market has begun. On July 24,
, the General Office of the National Health and Health Administration issued the "Special Action Plan for the Construction of The Style of the Medical Industry in 2020" (hereinafter referred to as the Action Plan), which aims to further strengthen the construction of medical and medical ethics of medical institutions, standardize the conduct of medical institutions and their practitioners in clean practice, and create a clean and clean industry environment.
rebates, general, unreasonable drug use, etc. are the focus of the style of rectification.
the strength of the anti-corruption of medicine constantly increased code, recently, many departments are also intensive on the purchase and sale of medicine in the sale of gold, commercial bribery and other issues issued rectification.
is understood that, in addition to the national rectification action, the pharmaceutical market adjustment news also came: in July, there has been the national pharmaceutical consistent, Hengrui Pharmaceuticals, Gan Li Pharmaceuticals and other 17 pharmaceutical companies executives left, 5 pharmaceutical companies were joined.
17 pharmaceutical company executives resigned 1, the national medicine agreement: July 31, the national pharmaceutical company issued a unanimous announcement that the company's board of directors recently received the company's vice chairman Ma Zhanjun submitted a written resignation report, because of the statutory retirement age, Ma Zhanjun no longer serves as the company's eighth vice chairman of the board of directors, director ship.
2, Xintian Pharmaceuticals: July 30, Guiyang Xintian Pharmaceuticals issued an announcement, Ms. Yuan Liping for personal reasons, applied to resign from the company's deputy general manager, the board of directors secretary.
3, Fangsheng Pharmaceuticals: July 29, Fangsheng Pharmaceuticals announced that Mr. Zhou Weien for personal reasons to apply to resign the company's deputy general manager and all positions held in the company's subsidiaries.
4, Hengrui Pharmaceuticals: July 24, Hengrui Pharmaceuticals announced that Jiang Xinhua, Sun Hui, Liu Ji, Mr. Li Kejian due to age reasons to apply to resign from the company's deputy general manager. After
resigned from the above positions, Mr. Jiang Xinhua, Sun Hui and Mr. Liu Ji were still working for the company.
5, Junshi Bio: July 24, Due to the internal regulations of individual stake, Mr. Chen Xinjun resigned as an independent non-executive director of the company and as a member of the nominating committee of the board of directors, a member of the audit committee, and a member of the remuneration and appraisal committee.
6, Guangji Pharmaceuticals: On July 23, Mr. Yu Zhongyi applied to resign as Deputy General Manager of the Company due to changes in his work, and Mr. Wang Shukun applied to resign as Chairman and Supervisor of the Company's 9th Supervisory Board because of job needs.
7, Gan Li Pharmaceuticals: July 20, Gan Li Pharmaceuticals announced that Mr. Gan Zhongru, Ms. Wang Dame, Mr. Ning Junjun for personal reasons, respectively, applied to resign as general manager, deputy general manager, finance head.
8, Watson Biology: On July 20, Watson Bio announcement stated that Mr. Zhong Bin had resigned from his position as an independent director of the company's 4th Board of Directors and as a member of the Strategic Committee of the Board of Directors, a member of the Nomination Committee and a member of the Remuneration and Appraisal Committee for personal reasons.
9, Hyundai Pharmaceuticals: July 15, Shanghai Hyundai Pharmaceuticals announced that Mr. Yang Jun resigned as director and president of the company for work reasons.
10, Chijin Pharmaceuticals: July 15, Zhuzhou Qianjin Pharmaceuticals announced that due to work adjustment reasons, Mr. Xie Aiwei applied to resign from the board of directors secretary.
11, Jingjing Pharmaceuticals: On July 14, Jingjing Pharmaceuticals announced that Mr. Xie Zhangqing had resigned as a director for personal reasons.
12, Hanyu Pharmaceuticals: July 13, Hanyu Pharmaceuticals announced that Ms. Wu Kexuan for personal reasons to apply to resign from the securities representative position.
13, sunflower medicine: July 8, sunflower pharmaceutical industry announced that, for personal reasons, Mr. Yu applied to resign as assistant to the general manager of the company, after resigning from other positions of the company.
14, unnamed creatures: On July 8, Shandong Unnamed Biopharmaceuticals announced that Mr. Wang Lijun had applied to resign as secretary of the company's board of directors for personal reasons.
15, Huahai Pharmaceuticals: July 3, Huahai Pharmaceuticals announced that Mr. Zhang Jiaai for personal reasons to apply to resign as vice president of the company.
16, Red Day Pharmaceuticals: July 2, Red Day Pharmaceuticals announced that due to job adjustment, Mr. QIAN XIAOLUN applied to resign as the company's deputy general manager, he resigned from the above position sits still working in the company.
17, Runda Medical: July 2, Shanghai Runda Medical Technology Co., Ltd. announced that Mr. Zhang Hongfeng resigned from his position as a staff supervisor for work reasons.
five pharmaceutical companies were and 1, the national medicine consistent: July 21, the national drug unanimously issued a public announcement that the proposed public de-listing into 100% of the shares of Dafang Yuan Pharmaceutical Group Co., Ltd., the public listing transfer floor price of 186,000.00 million yuan.
2, Guizhou Sanli Pharmaceuticals: July 20, Guizhou Sanli Pharmaceuticals issued a notice, intended to cash to Guizhou Hanfang Pharmaceutical Co., Ltd., Guiyang Dechangxiang Pharmaceutical Co., Ltd. to increase capital, to obtain Hanfang Pharmaceutical, Dechangxiang Pharmaceuticals not more than 51% of the equity.
3, Haizheng Pharmaceuticals: On July 20, Haizheng Pharmaceuticals announced that it intends to issue shares, convertible corporate bonds and cash to HPPC to buy its 49% stake in Hanyu Pharmaceuticals. At the same time
, the total amount of supporting funds to be raised shall not exceed 1.5 billion yuan.
4, Huafeng PharmaceuticalS: July 6, Hubei Province Drug Administration issued a notice that Feng County Huafeng Pharmaceutical Co., Ltd. merger and reorganization, the new declaration issued By Hubei Xuanming Pharmaceutical Technology Co., Ltd. "drug business license."
5, Guangshengtang: July 1, Guangshengtang issued a notice, the company and holding subsidiary ZTE Pharmaceutical minority shareholders Pan Lifei, Pan Liqiang signed the "Equity Transfer Agreement", respectively, with 5.25 million yuan for the purchase of Pan Lifei, Pan Liqiang each held 5% of ZTE Pharmaceuticals.
the deal is completed, the company will take a 92.5% stake in ZTE Pharmaceuticals.
... Since 2020, with China's medical reform into the deep water area, especially under the pressure of volume procurement, consistency evaluation, and anti-corruption upgrade of medical reform, generic drug prices have dived into the era of micro-profits, and under the frequent action of drug review and approval system reform, medical insurance catalog adjustment, innovative drugs have become a new breakthrough direction.
in this context, the domestic pharmaceutical market to lead the situation of generic drugs will be broken, drug prices will fall, drug quality will improve, the entire industry is facing major changes in transformation and upgrading.
this means that in the next few years, China's pharmaceutical industry will continue to shake.
Source: Pharmaceutical Cloud Studio, Pharmaceutical Information Local Desk.